Ken Griffin Siga Technologies Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.74 - $11.97 $240,618 - $427,329	35,700 Added 27.78%	164,200 $1.11 Million
Q2 2024 Aug 14, 2024	BUY	$6.32 - $10.46 $93,536 - $154,808	14,800 Added 13.02%	128,500 $975,000
Q1 2024 May 15, 2024	SELL	$4.51 - $8.92 $119,515 - $236,380	-26,500 Reduced 18.9%	113,700 $973,000
Q4 2023 Feb 14, 2024	SELL	$4.82 - $6.25 $48,682 - $63,125	-10,100 Reduced 6.72%	140,200 $785,000
Q3 2023 Nov 14, 2023	SELL	$4.32 - $5.77 $35,856 - $47,891	-8,300 Reduced 5.23%	150,300 $789,000
Q2 2023 Aug 14, 2023	SELL	$5.0 - $6.31 $129,500 - $163,429	-25,900 Reduced 14.04%	158,600 $800,000
Q1 2023 May 15, 2023	SELL	$5.23 - $8.42 $228,028 - $367,112	-43,600 Reduced 19.11%	184,500 $1.06 Million
Q4 2022 Feb 14, 2023	SELL	$7.29 - $10.14 $2.77 Million - $3.85 Million	-379,400 Reduced 62.45%	228,100 $1.68 Million
Q3 2022 Nov 14, 2022	BUY	$10.02 - $26.15 $4.3 Million - $11.2 Million	429,100 Added 240.53%	607,500 $6.26 Million

185

35.6M

873K

466K

Ticker SIGA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 73,024,096
Market Cap $438M
Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.